Abstract
Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.
Keywords: Neuroendocrine tumors, biomarkers, somatostatin analogs, angiogenesis inhibitors, cytotoxic chemotherapy, radionuclide therapy, liver-targeted therapies.
Anti-Cancer Agents in Medicinal Chemistry
Title:Therapeutic Challenges in Neuroendocrine Tumors
Volume: 17 Issue: 7
Author(s): Ioannis Legakis*, Muhammad Wasif Saif and Kostantinos Syrigos
Affiliation:
- Oncology Unit, 3rd Department of Internal Medicine, Sotiria General Hospital, Athens School of Medicine, Athens,Greece
Keywords: Neuroendocrine tumors, biomarkers, somatostatin analogs, angiogenesis inhibitors, cytotoxic chemotherapy, radionuclide therapy, liver-targeted therapies.
Abstract: Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.
Export Options
About this article
Cite this article as:
Legakis Ioannis*, Saif Wasif Muhammad and Syrigos Kostantinos, Therapeutic Challenges in Neuroendocrine Tumors, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520617666170213113401
DOI https://dx.doi.org/10.2174/1871520617666170213113401 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 9
Current Pharmaceutical Design The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Preface
Current Pharmaceutical Design Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Biological Roles of the Eclectic Chromogranin-A-derived Peptide Catestatin
Current Medicinal Chemistry Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology